Search Results - "Hart, L.L."

Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) in MONALEESA-2 by Sonke, G.S, Hart, L.L, Campone, M, Erdkamp, F, Janni, W, Verma, S, Villanueva, C, Jakobsen, E, Alba, E, Wist, E, Favret, A.M, Bachelot, T, Hegg, R, Wheatley-Price, P, Souami, F, Sutradhar, S, Miller, M, Germa, C, Burris, H.A

Get full text

Adjuvant systemic therapy in women with early breast cancer and intermediate prosigna ROR scores: Is chemotherapy use declining? Evidence from a large practice by Hart, L.L., den Bergh, M.V.

Get full text

202P - Adjuvant systemic therapy in women with early breast cancer and intermediate prosigna ROR scores: Is chemotherapy use declining? Evidence from a large practice by Hart, L.L., den Bergh, M.V.

“…Decision making on adjuvant systemic therapy in women with primary node-negative, HR+ breast cancer and intermediate risk scores on a molecular tumor profile…”
Get full text

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial by Weiss, J.M., Csoszi, T., Maglakelidze, M., Hoyer, R.J., Beck, J.T., Domine Gomez, M., Lowczak, A., Aljumaily, R., Rocha Lima, C.M., Boccia, R.V., Hanna, W., Nikolinakos, P., Chiu, V.K., Owonikoko, T.K., Schuster, S.R., Hussein, M.A., Richards, D.A., Sawrycki, P., Bulat, I., Hamm, J.T., Hart, L.L., Adler, S., Antal, J.M., Lai, A.Y., Sorrentino, J.A., Yang, Z., Malik, R.K., Morris, S.R., Roberts, P.J., Dragnev, K.H.

“…Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6…”
Get full text

2LBA - Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) in MONALEESA-2 by Sonke, G.S., Hart, L.L., Campone, M., Erdkamp, F., Janni, W., Verma, S., Villanueva, C., Jakobsen, E., Alba, E., Wist, E., Favret, A.M., Bachelot, T., Hegg, R., Wheatley-Price, P., Souami, F., Sutradhar, S., Miller, M., Germa, C., Burris, H.A.

Get full text

A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma by Ott, P.A., Pavlick, A.C., Johnson, D.B., Hart, L.L., Infante, J.R., Luke, J.J., Lutzky, J., Rothschild, N., Spitler, L., Cowey, C.L., Alizadeh, A., Salama, A., He, Y., Bagley, R.G., Zhang, J., Hamid, O.

Get full text

Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study by Mahalingam, D., Patel, M.R., Sachdev, J.C., Hart, L.L., Halama, N., Ramanathan, R.K., Sarantopoulos, J., Liu, X., Yazji, S., Jäger, D., Yoon, M., Manzur, G.Ç, Adib, D., Kerschbaumer, R., Tsimberidou, A.

Get full text

Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer by Seidman, A.D., Brufsky, A., Ansari, R.H., Hart, L.L., Stein, R.S., Schwartzberg, L.S., Stewart, J.F., Russell, C.A., Chen, S.-C., Fein, L.E., De La Cruz Vargas, J.A., Kim, S.-B., Cavalheiro, J., Zhao, L., Gill, J.F., Obasaju, C.K., Orlando, M., Tai, D.F.

“…Safety and efficacy of gemcitabine plus docetaxel (GD) and capecitabine plus docetaxel (CD) were compared in patients with metastatic breast cancer, where the…”
Get full text